|
|
 |
|
Viewing report
|
|
|
|
Germany Pharmaceutical Market Overview - New pricing rules set to negatively impact drug sales both domestically and internationally
Datamonitor, Dec 2010, Pages: 267
The German prescription pharmaceutical market was valued at $38.3 bn in 2009, with an annual growth rate of 4.4% between 2008 and 2009. However, future market growth will be hampered by the newly introduced price negotiation requirements in addition to raised rebates for patent protected drugs, with an impact on other countries that use Germany as a reference market.
Scope of the report:
- Overview of socioeconomic and demographic trends, healthcare system, regulation, pricing and reimbursement and intellectual property in Germany
- Assesses the size of the Germany pharmaceutical market by prescribing setting, therapy area, leading brands and by leading companies
- Examines the Germany generics and biosimilars landscape in terms of regulatory issues, level of penetration, key players and degree of brand erosion
- Quantifies the R&D and manufacturing infrastructure for the leading pharmaceutical companies, including key metrics and domestic M&A analysis
Highlights:
Low birth rate in Germany has led to a demographic crisis prompting the need for social security reforms despite the country’s swift recovery from the economic downturn. Cuts are impacting the healthcare sector with pharmaceuticals also feeling the sting.
New drug price negotiation requirements will give more leverage to health insurance funds. With an expected downward pressure on price, the impact will be felt domestically as well as internationally.
Generics uptake is already high and the latest cost-containment measures including tendering contracts for generics have led to downward pricing spirals, negatively impacting the domestic generics industry.
Biosimilars are also gaining ground and are becoming a real threat for biologics producers.
Reasons to buy:
- Evaluate the evolving regulatory landscape and the impact of pricing and reimbursement controls on market access in Germany
- Quantify the size and growth of the prescription pharmaceutical market in Germany, analyzing key therapy areas, brands and companies
- Assess drivers and resistors of generic and biosimilars uptake in Germany
|
|
|
|
